Epitranscriptomics in atherosclerosis: Unraveling RNA modifications, editing and splicing and their implications in vascular disease
Vascular Pharmacology · 2025
DOI: 10.1016/j.vph.2025.107496 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2025. Verfasst von Victoria Stopa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg. Hauptthemen laut MEDLINE: Atherosclerosis, RNA Editing, Epigenesis, Genetic, RNA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Cooperation in Science and Technology, National Research Fund, Novo Nordisk Fonden.
Abstract (Originalsprache)
Atherosclerosis remains a leading cause of morbidity and mortality worldwide, driven by complex molecular mechanisms involving gene regulation and post-transcriptional processes. Emerging evidence highlights the critical role of epitranscriptomics, the study of chemical modifications occurring on RNA molecules, in atherosclerosis development. Epitranscriptomics provides a new layer of regulation in vascular health, influencing cellular functions in endothelial cells, smooth muscle cells, and macrophages, thereby shedding light on the pathogenesis of atherosclerosis and presenting new opportunities for novel therapeutic targets. This review provides a comprehensive overview of the epitranscriptomic landscape, focusing on key RNA modifications such as N6-methyladenosine (m6A), 5-methylcytosine (m5C), pseudouridine (Ψ), RNA editing mechanisms including A-to-I and C-to-U editing and RNA isoforms. The functional implications of these modifications in RNA stability, alternative splicing, and microRNA biology are discussed, with a focus on their roles in inflammatory signaling, lipid metabolism, and vascular cell adaptation within atherosclerotic plaques. We also highlight how these modifications influence the generation of RNA isoforms, potentially altering cellular phenotypes and contributing to disease progression. Despite the promise of epitranscriptomics, significant challenges remain, including the technical limitations in detecting RNA modifications in complex tissues and the need for deeper mechanistic insights into their causal roles in atherosclerotic pathogenesis. Integrating epitranscriptomics with other omics approaches, such as genomics, proteomics, and metabolomics, holds the potential to provide a more holistic understanding of the disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg.
- Department of Genetics, Development and Molecular Biology, School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Denmark.
- Department of Applied Biomedical Science, Faculty of Health Sciences, University of Malta, Msida, Malta.
- Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg. Electronic address: yvan.devaux@lih.lu.
- Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Förderung
- European Cooperation in Science and Technology
- National Research Fund
- Novo Nordisk Fonden
- Hellenic Foundation for Research and Innovation
- Horizon Europe
- Innovative Medicines Initiative
- Horizon 2020 Framework Programme
- Ministère de l'Enseignement supérieur et de la Recherche
Zitieren
APA
Stopa, V., Dafou, D., Karagianni, K., Nossent, A. Y., Farrugia, R., Devaux, Y., Sopic, M., & AtheroNET COST Action CA21153 (www.atheronet.eu) (2025). Epitranscriptomics in atherosclerosis: Unraveling RNA modifications, editing and splicing and their implications in vascular disease. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2025.107496
Vancouver
Stopa V, Dafou D, Karagianni K, Nossent AY, Farrugia R, Devaux Y, et al. Epitranscriptomics in atherosclerosis: Unraveling RNA modifications, editing and splicing and their implications in vascular disease. Vascular Pharmacology. 2025. doi:10.1016/j.vph.2025.107496
BibTeX
@article{Stopa2025,
author = {Stopa, Victoria and Dafou, Dimitra and Karagianni, Korina and Nossent, A Yaël and Farrugia, Rosienne and Devaux, Yvan and Sopic, Miron and AtheroNET COST Action CA21153 (www.atheronet.eu), AtheroNET COST Action CA21153 (www.atheronet.eu)},
title = {Epitranscriptomics in atherosclerosis: Unraveling RNA modifications, editing and splicing and their implications in vascular disease},
journal = {Vascular Pharmacology},
year = {2025},
doi = {10.1016/j.vph.2025.107496}
}
EUVIMED